세계의 당뇨병성 신경병증 치료 시장 규모, 점유율, 동향 분석 : 유통 채널별, 약제 클래스별, 질환 유형별, 지역별 전망과 예측(2024-2031년)

Global Diabetic Neuropathy Treatment Market Size, Share & Trends Analysis Report By Distribution Channel, By Drug Class, By Disorder Type, By Regional Outlook and Forecast, 2024 - 2031

US $ 3,600 ￦ 5,019,000

PDF (Single User License)

PDF 보고서를 1명만 이용할 수 있는 라이선스입니다. 텍스트의 Copy & Paste 가능합니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

US $ 4,320 ￦ 6,023,000

PDF (Multi User License)

PDF 보고서를 동일 기업의 10명까지 이용할 수 있는 라이선스입니다. 텍스트의 Copy & Paste 가능합니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

US $ 6,048 ￦ 8,432,000

PDF (Corporate User License)

PDF 보고서를 동일 기업의 모든 분이 이용할 수 있는 라이선스입니다. 텍스트의 Copy & Paste 가능합니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

한글목차

세계의 당뇨병성 신경병증 치료 시장 규모는 2031년까지 74억 달러에 달하며, 예측 기간 중 CAGR 7.3%로 성장할 것으로 예측되고 있습니다.

또한 세계보건기구에 따르면 2014년 18세 이상 성인의 당뇨병 환자 비율은 8.5%였으며, 2019년에는 당뇨병으로 인해 150만 명이 사망했고, 당뇨병 관련 사망자의 48%는 70세 미만에서 발생했다고 합니다. 또한 신장 질환으로 인한 사망자도 46만 명에 달할 전망입니다. 따라서 전 세계에서 당뇨병 유병률이 증가하고 있는 것이 시장의 주요 원동력이 되고 있습니다.

그러나 많은 당뇨병 환자들은 장기간 혈당이 조절되지 않으면 신경장애와 같은 합병증이 발생할 수 있다는 사실을 인지하지 못하는 경우가 많습니다. 이러한 인식 부족으로 인해 손발 저림, 따끔거림, 통증 등 신경 장애를 시사하는 증상이 처음 나타났을 때 의사의 진찰을 받는 것이 늦어질 수 있습니다. 따라서 치료법이 채택될 수 있는 이 질병에 대한 인식 부족은 시장 성장을 저해할 수 있습니다.

목차

제1장 시장 범위와 조사 방법

• 시장의 정의
• 목적
• 시장 범위
• 세분화
• 조사 방법

제2장 시장 요약

• 주요 하이라이트

제3장 시장 개요

• 서론
  • 개요
    • 시장 구성과 시나리오
• 시장에 영향을 미치는 주요 요인
  • 시장 촉진요인
  • 시장 억제요인
  • 시장 기회
  • 시장이 해결해야 할 과제
• Porter's Five Forces 분석

제4장 세계의 당뇨병성 신경병증 치료 시장 : 유통 채널별

• 세계의 원내 약국 시장 : 지역별
• 세계의 소매 약국 시장 : 지역별
• 세계의 기타 시장 : 지역별

제5장 세계의 당뇨병성 신경병증 치료 시장 : 약제 클래스별

• 세계의 비스테로이드성 항염증약(NSAID) 시장 : 지역별
• 세계의 항우울제 시장 : 지역별
• 세계의 오피오이드 시장 : 지역별
• 세계의 캡사이신 시장 : 지역별
• 세계의 기타 시장 : 지역별

제6장 세계의 당뇨병성 신경병증 치료 시장 : 질환 유형별

• 세계의 말초신경병증 시장 : 지역별
• 세계의 자율신경 장애 시장 : 지역별
• 세계의 근위신경장애 시장 : 지역별
• 세계의 국소성 신경장애 시장 : 지역별

제7장 세계의 당뇨병성 신경병증 치료 시장 : 지역별

• 북미
  • 북미의 당뇨병성 신경병증 치료 시장 : 국가별
    • 미국
    • 캐나다
    • 멕시코
    • 기타 북미
• 유럽
  • 유럽의 당뇨병성 신경병증 치료 시장 : 국가별
    • 독일
    • 영국
    • 프랑스
    • 러시아
    • 스페인
    • 이탈리아
    • 기타 유럽
• 아시아태평양
  • 아시아태평양의 당뇨병성 신경병증 치료 시장 : 국가별
    • 중국
    • 일본
    • 인도
    • 한국
    • 호주
    • 말레이시아
    • 기타 아시아태평양
• 라틴아메리카·중동 및 아프리카
  • 라틴아메리카·중동 및 아프리카의 당뇨병성 신경병증 치료 시장 : 국가별
    • 브라질
    • 아르헨티나
    • 아랍에미리트
    • 사우디아라비아
    • 남아프리카공화국
    • 나이지리아
    • 기타 라틴아메리카·중동 및 아프리카

제8장 기업 개요

• Abbott Laboratories
• Eli Lilly And Company
• Pfizer, Inc
• Lupin Limited
• Astellas Pharma, Inc
• Glenmark Pharmaceuticals Limited
• Boehringer Ingelheim International GmbH
• Novartis AG
• McKesson Corporation
• GlaxoSmithKline PLC(GSK)

제9장 당뇨병성 신경병증 치료 시장의 성공 필수 조건

KSA

영문 목차

영문목차

The Global Diabetic Neuropathy Treatment Market size is expected to reach $7.4 billion by 2031, rising at a market growth of 7.3% CAGR during the forecast period.

The demand for diabetic neuropathy treatment in North America is increasing due to several factors. Increasing diabetes prevalence in the region is among the primary factors. Thus, the North America region captured 39.5% revenue share in the market 2023. With high rates of smoking in Canada, there is a greater prevalence of diabetes and diabetic neuropathy among the population, leading to increased demand for this.

Advancements in treating diabetic neuropathy have made significant progress in recent years, offering patients a broader array of options to manage their condition effectively. One key area of advancement is pharmacological therapies. Novel medications have been developed that target specific pathways involved in nerve damage, such as inflammation and oxidative stress.

Additionally, as per the World Health Organization, the proportion of diabetic people among adults aged 18 years and older was 8.5% in 2014. Diabetes accounted for the direct cause of 1.5 million fatalities in 2019, with 48% of diabetes-related deaths occurring in individuals younger than 70 years of age. Diabetes accounted for an additional 460,000 fatalities due to kidney disease. Thus, the increasing prevalence of diabetes worldwide is a key driver of the market.

However, many people with diabetes may not be aware of the potential complications, including neuropathy, which can result from uncontrolled blood sugar levels over time. Such a lack of awareness may result in postponing the pursuit of medical attention upon the initial appearance of symptoms indicative of neuropathy, including numbness, tingling, or pain in the hands and feet. Hence, the lack of awareness of the disease may allow the adoption of treatments and hamper the market's growth.

By Distribution Channel Analysis

By distribution channel, the market is divided into hospital pharmacies, retail pharmacies, and others. The hospital pharmacies segment witnessed 47.8% revenue share in the market in 2023. Hospital pharmacies serve a vital function in furnishing patients with the proper medications prescribed for diabetic neuropathy.

By Drug Class Analysis

On the basis of drug class, the market is classified into capsaicin, opioid, non-steroidal anti-inflammatory drugs (NSAIDs), antidepressants, and others. The antidepressants segment recorded 29.3% revenue share in the market in 2022.

By Disorder Analysis

Based on disorder type, the market is characterized into peripheral neuropathy, autonomic neuropathy, proximal neuropathy, and focal neuropathy. The peripheral neuropathy segment garnered 63.8% revenue share in the market in 2023. There are many different causes of peripheral neuropathy, including diabetes, infections, exposure to toxins, and certain medications.

By Regional Analysis

Region-wise, the market is analyzed across North America, Europe, Asia Pacific, and LAMEA. The Asia Pacific segment acquired 26.9% revenue share in the market in 2023. Based on data from the International Diabetes Federation, this region is anticipated to have the highest prevalence of diabetes in 2021, with an estimated 191 million adults aged 20-79 affected.

List of Key Companies Profiled

• Abbott Laboratories
• Eli Lilly And Company
• Pfizer, Inc.
• Lupin Limited
• Astellas Pharma, Inc.
• Glenmark Pharmaceuticals Limited
• Boehringer Ingelheim International GmbH
• Novartis AG
• McKesson Corporation
• GlaxoSmithKline PLC (GSK)

Global Diabetic Neuropathy Treatment Market Report Segmentation

By Distribution Channel

• Hospitals Pharmacies
• Retail Pharmacies
• Others

By Drug Class

• Non-Steroidal Anti-inflammatory Drugs (NSAIDs)
• Antidepressants
• Opioid
• Capsaicin
• Others

By Disorder Type

• Peripheral Neuropathy
• Autonomic Neuropathy
• Proximal Neuropathy
• Focal Neuropathy

By Geography

• North America
  • US
  • Canada
  • Mexico
  • Rest of North America
• Europe
  • Germany
  • UK
  • France
  • Russia
  • Spain
  • Italy
  • Rest of Europe
• Asia Pacific
  • China
  • Japan
  • India
  • South Korea
  • Australia
  • Malaysia
  • Rest of Asia Pacific
• LAMEA
  • Brazil
  • Argentina
  • UAE
  • Saudi Arabia
  • South Africa
  • Nigeria
  • Rest of LAMEA

Table of Contents

Chapter 1.Market Scope & Methodology

• 1.1Market Definition
• 1.2Objectives
• 1.3Market Scope
• 1.4Segmentation
  • 1.4.1Global Diabetic Neuropathy Treatment Market, by Distribution Channel
  • 1.4.2Global Diabetic Neuropathy Treatment Market, by Drug Class
  • 1.4.3Global Diabetic Neuropathy Treatment Market, by Disorder Type
  • 1.4.4Global Diabetic Neuropathy Treatment Market, by Geography
• 1.5Methodology for the research

Chapter 2.Market at a Glance

• 2.1Key Highlights

Chapter 3.Market Overview

• 3.1Introduction
  • 3.1.1Overview
    • 3.1.1.1Market Composition and Scenario
• 3.2Key Factors Impacting the Market
  • 3.2.1Market Drivers
  • 3.2.2Market Restraints
  • 3.2.3Market Opportunities
  • 3.2.4Market Challenges
• 3.3Porter Five Forces Analysis

Chapter 4.Global Diabetic Neuropathy Treatment Market by Distribution Channel

• 4.1Global Hospitals Pharmacies Market by Region
• 4.2Global Retail Pharmacies Market by Region
• 4.3Global Others Market by Region

Chapter 5.Global Diabetic Neuropathy Treatment Market by Drug Class

• 5.1Global Non-Steroidal Anti-inflammatory Drugs (NSAIDs) Market by Region
• 5.2Global Antidepressants Market by Region
• 5.3Global Opioid Market by Region
• 5.4Global Capsaicin Market by Region
• 5.5Global Others Market by Region

Chapter 6.Global Diabetic Neuropathy Treatment Market by Disorder Type

• 6.1Global Peripheral Neuropathy Market by Region
• 6.2Global Autonomic Neuropathy Market by Region
• 6.3Global Proximal Neuropathy Market by Region
• 6.4Global Focal Neuropathy Market by Region

Chapter 7.Global Diabetic Neuropathy Treatment Market by Region

• 7.1North America Diabetic Neuropathy Treatment Market
  • 7.1.1North America Diabetic Neuropathy Treatment Market by Distribution Channel
    • 7.1.1.1North America Hospitals Pharmacies Market by Country
    • 7.1.1.2North America Retail Pharmacies Market by Country
    • 7.1.1.3North America Others Market by Country
  • 7.1.2North America Diabetic Neuropathy Treatment Market by Drug Class
    • 7.1.2.1North America Non-Steroidal Anti-inflammatory Drugs (NSAIDs) Market by Country
    • 7.1.2.2North America Antidepressants Market by Country
    • 7.1.2.3North America Opioid Market by Country
    • 7.1.2.4North America Capsaicin Market by Country
    • 7.1.2.5North America Others Market by Country
  • 7.1.3North America Diabetic Neuropathy Treatment Market by Disorder Type
    • 7.1.3.1North America Peripheral Neuropathy Market by Country
    • 7.1.3.2North America Autonomic Neuropathy Market by Country
    • 7.1.3.3North America Proximal Neuropathy Market by Country
    • 7.1.3.4North America Focal Neuropathy Market by Country
  • 7.1.4North America Diabetic Neuropathy Treatment Market by Country
    • 7.1.4.1US Diabetic Neuropathy Treatment Market
      • 7.1.4.1.1US Diabetic Neuropathy Treatment Market by Distribution Channel
      • 7.1.4.1.2US Diabetic Neuropathy Treatment Market by Drug Class
      • 7.1.4.1.3US Diabetic Neuropathy Treatment Market by Disorder Type
    • 7.1.4.2Canada Diabetic Neuropathy Treatment Market
      • 7.1.4.2.1Canada Diabetic Neuropathy Treatment Market by Distribution Channel
      • 7.1.4.2.2Canada Diabetic Neuropathy Treatment Market by Drug Class
      • 7.1.4.2.3Canada Diabetic Neuropathy Treatment Market by Disorder Type
    • 7.1.4.3Mexico Diabetic Neuropathy Treatment Market
      • 7.1.4.3.1Mexico Diabetic Neuropathy Treatment Market by Distribution Channel
      • 7.1.4.3.2Mexico Diabetic Neuropathy Treatment Market by Drug Class
      • 7.1.4.3.3Mexico Diabetic Neuropathy Treatment Market by Disorder Type
    • 7.1.4.4Rest of North America Diabetic Neuropathy Treatment Market
      • 7.1.4.4.1Rest of North America Diabetic Neuropathy Treatment Market by Distribution Channel
      • 7.1.4.4.2Rest of North America Diabetic Neuropathy Treatment Market by Drug Class
      • 7.1.4.4.3Rest of North America Diabetic Neuropathy Treatment Market by Disorder Type
• 7.2Europe Diabetic Neuropathy Treatment Market
  • 7.2.1Europe Diabetic Neuropathy Treatment Market by Distribution Channel
    • 7.2.1.1Europe Hospitals Pharmacies Market by Country
    • 7.2.1.2Europe Retail Pharmacies Market by Country
    • 7.2.1.3Europe Others Market by Country
  • 7.2.2Europe Diabetic Neuropathy Treatment Market by Drug Class
    • 7.2.2.1Europe Non-Steroidal Anti-inflammatory Drugs (NSAIDs) Market by Country
    • 7.2.2.2Europe Antidepressants Market by Country
    • 7.2.2.3Europe Opioid Market by Country
    • 7.2.2.4Europe Capsaicin Market by Country
    • 7.2.2.5Europe Others Market by Country
  • 7.2.3Europe Diabetic Neuropathy Treatment Market by Disorder Type
    • 7.2.3.1Europe Peripheral Neuropathy Market by Country
    • 7.2.3.2Europe Autonomic Neuropathy Market by Country
    • 7.2.3.3Europe Proximal Neuropathy Market by Country
    • 7.2.3.4Europe Focal Neuropathy Market by Country
  • 7.2.4Europe Diabetic Neuropathy Treatment Market by Country
    • 7.2.4.1Germany Diabetic Neuropathy Treatment Market
      • 7.2.4.1.1Germany Diabetic Neuropathy Treatment Market by Distribution Channel
      • 7.2.4.1.2Germany Diabetic Neuropathy Treatment Market by Drug Class
      • 7.2.4.1.3Germany Diabetic Neuropathy Treatment Market by Disorder Type
    • 7.2.4.2UK Diabetic Neuropathy Treatment Market
      • 7.2.4.2.1UK Diabetic Neuropathy Treatment Market by Distribution Channel
      • 7.2.4.2.2UK Diabetic Neuropathy Treatment Market by Drug Class
      • 7.2.4.2.3UK Diabetic Neuropathy Treatment Market by Disorder Type
    • 7.2.4.3France Diabetic Neuropathy Treatment Market
      • 7.2.4.3.1France Diabetic Neuropathy Treatment Market by Distribution Channel
      • 7.2.4.3.2France Diabetic Neuropathy Treatment Market by Drug Class
      • 7.2.4.3.3France Diabetic Neuropathy Treatment Market by Disorder Type
    • 7.2.4.4Russia Diabetic Neuropathy Treatment Market
      • 7.2.4.4.1Russia Diabetic Neuropathy Treatment Market by Distribution Channel
      • 7.2.4.4.2Russia Diabetic Neuropathy Treatment Market by Drug Class
      • 7.2.4.4.3Russia Diabetic Neuropathy Treatment Market by Disorder Type
    • 7.2.4.5Spain Diabetic Neuropathy Treatment Market
      • 7.2.4.5.1Spain Diabetic Neuropathy Treatment Market by Distribution Channel
      • 7.2.4.5.2Spain Diabetic Neuropathy Treatment Market by Drug Class
      • 7.2.4.5.3Spain Diabetic Neuropathy Treatment Market by Disorder Type
    • 7.2.4.6Italy Diabetic Neuropathy Treatment Market
      • 7.2.4.6.1Italy Diabetic Neuropathy Treatment Market by Distribution Channel
      • 7.2.4.6.2Italy Diabetic Neuropathy Treatment Market by Drug Class
      • 7.2.4.6.3Italy Diabetic Neuropathy Treatment Market by Disorder Type
    • 7.2.4.7Rest of Europe Diabetic Neuropathy Treatment Market
      • 7.2.4.7.1Rest of Europe Diabetic Neuropathy Treatment Market by Distribution Channel
      • 7.2.4.7.2Rest of Europe Diabetic Neuropathy Treatment Market by Drug Class
      • 7.2.4.7.3Rest of Europe Diabetic Neuropathy Treatment Market by Disorder Type
• 7.3Asia Pacific Diabetic Neuropathy Treatment Market
  • 7.3.1Asia Pacific Diabetic Neuropathy Treatment Market by Distribution Channel
    • 7.3.1.1Asia Pacific Hospitals Pharmacies Market by Country
    • 7.3.1.2Asia Pacific Retail Pharmacies Market by Country
    • 7.3.1.3Asia Pacific Others Market by Country
  • 7.3.2Asia Pacific Diabetic Neuropathy Treatment Market by Drug Class
    • 7.3.2.1Asia Pacific Non-Steroidal Anti-inflammatory Drugs (NSAIDs) Market by Country
    • 7.3.2.2Asia Pacific Antidepressants Market by Country
    • 7.3.2.3Asia Pacific Opioid Market by Country
    • 7.3.2.4Asia Pacific Capsaicin Market by Country
    • 7.3.2.5Asia Pacific Others Market by Country
  • 7.3.3Asia Pacific Diabetic Neuropathy Treatment Market by Disorder Type
    • 7.3.3.1Asia Pacific Peripheral Neuropathy Market by Country
    • 7.3.3.2Asia Pacific Autonomic Neuropathy Market by Country
    • 7.3.3.3Asia Pacific Proximal Neuropathy Market by Country
    • 7.3.3.4Asia Pacific Focal Neuropathy Market by Country
  • 7.3.4Asia Pacific Diabetic Neuropathy Treatment Market by Country
    • 7.3.4.1China Diabetic Neuropathy Treatment Market
      • 7.3.4.1.1China Diabetic Neuropathy Treatment Market by Distribution Channel
      • 7.3.4.1.2China Diabetic Neuropathy Treatment Market by Drug Class
      • 7.3.4.1.3China Diabetic Neuropathy Treatment Market by Disorder Type
    • 7.3.4.2Japan Diabetic Neuropathy Treatment Market
      • 7.3.4.2.1Japan Diabetic Neuropathy Treatment Market by Distribution Channel
      • 7.3.4.2.2Japan Diabetic Neuropathy Treatment Market by Drug Class
      • 7.3.4.2.3Japan Diabetic Neuropathy Treatment Market by Disorder Type
    • 7.3.4.3India Diabetic Neuropathy Treatment Market
      • 7.3.4.3.1India Diabetic Neuropathy Treatment Market by Distribution Channel
      • 7.3.4.3.2India Diabetic Neuropathy Treatment Market by Drug Class
      • 7.3.4.3.3India Diabetic Neuropathy Treatment Market by Disorder Type
    • 7.3.4.4South Korea Diabetic Neuropathy Treatment Market
      • 7.3.4.4.1South Korea Diabetic Neuropathy Treatment Market by Distribution Channel
      • 7.3.4.4.2South Korea Diabetic Neuropathy Treatment Market by Drug Class
      • 7.3.4.4.3South Korea Diabetic Neuropathy Treatment Market by Disorder Type
    • 7.3.4.5Australia Diabetic Neuropathy Treatment Market
      • 7.3.4.5.1Australia Diabetic Neuropathy Treatment Market by Distribution Channel
      • 7.3.4.5.2Australia Diabetic Neuropathy Treatment Market by Drug Class
      • 7.3.4.5.3Australia Diabetic Neuropathy Treatment Market by Disorder Type
    • 7.3.4.6Malaysia Diabetic Neuropathy Treatment Market
      • 7.3.4.6.1Malaysia Diabetic Neuropathy Treatment Market by Distribution Channel
      • 7.3.4.6.2Malaysia Diabetic Neuropathy Treatment Market by Drug Class
      • 7.3.4.6.3Malaysia Diabetic Neuropathy Treatment Market by Disorder Type
    • 7.3.4.7Rest of Asia Pacific Diabetic Neuropathy Treatment Market
      • 7.3.4.7.1Rest of Asia Pacific Diabetic Neuropathy Treatment Market by Distribution Channel
      • 7.3.4.7.2Rest of Asia Pacific Diabetic Neuropathy Treatment Market by Drug Class
      • 7.3.4.7.3Rest of Asia Pacific Diabetic Neuropathy Treatment Market by Disorder Type
• 7.4LAMEA Diabetic Neuropathy Treatment Market
  • 7.4.1LAMEA Diabetic Neuropathy Treatment Market by Distribution Channel
    • 7.4.1.1LAMEA Hospitals Pharmacies Market by Country
    • 7.4.1.2LAMEA Retail Pharmacies Market by Country
    • 7.4.1.3LAMEA Others Market by Country
  • 7.4.2LAMEA Diabetic Neuropathy Treatment Market by Drug Class
    • 7.4.2.1LAMEA Non-Steroidal Anti-inflammatory Drugs (NSAIDs) Market by Country
    • 7.4.2.2LAMEA Antidepressants Market by Country
    • 7.4.2.3LAMEA Opioid Market by Country
    • 7.4.2.4LAMEA Capsaicin Market by Country
    • 7.4.2.5LAMEA Others Market by Country
  • 7.4.3LAMEA Diabetic Neuropathy Treatment Market by Disorder Type
    • 7.4.3.1LAMEA Peripheral Neuropathy Market by Country
    • 7.4.3.2LAMEA Autonomic Neuropathy Market by Country
    • 7.4.3.3LAMEA Proximal Neuropathy Market by Country
    • 7.4.3.4LAMEA Focal Neuropathy Market by Country
  • 7.4.4LAMEA Diabetic Neuropathy Treatment Market by Country
    • 7.4.4.1Brazil Diabetic Neuropathy Treatment Market
      • 7.4.4.1.1Brazil Diabetic Neuropathy Treatment Market by Distribution Channel
      • 7.4.4.1.2Brazil Diabetic Neuropathy Treatment Market by Drug Class
      • 7.4.4.1.3Brazil Diabetic Neuropathy Treatment Market by Disorder Type
    • 7.4.4.2Argentina Diabetic Neuropathy Treatment Market
      • 7.4.4.2.1Argentina Diabetic Neuropathy Treatment Market by Distribution Channel
      • 7.4.4.2.2Argentina Diabetic Neuropathy Treatment Market by Drug Class
      • 7.4.4.2.3Argentina Diabetic Neuropathy Treatment Market by Disorder Type
    • 7.4.4.3UAE Diabetic Neuropathy Treatment Market
      • 7.4.4.3.1UAE Diabetic Neuropathy Treatment Market by Distribution Channel
      • 7.4.4.3.2UAE Diabetic Neuropathy Treatment Market by Drug Class
      • 7.4.4.3.3UAE Diabetic Neuropathy Treatment Market by Disorder Type
    • 7.4.4.4Saudi Arabia Diabetic Neuropathy Treatment Market
      • 7.4.4.4.1Saudi Arabia Diabetic Neuropathy Treatment Market by Distribution Channel
      • 7.4.4.4.2Saudi Arabia Diabetic Neuropathy Treatment Market by Drug Class
      • 7.4.4.4.3Saudi Arabia Diabetic Neuropathy Treatment Market by Disorder Type
    • 7.4.4.5South Africa Diabetic Neuropathy Treatment Market
      • 7.4.4.5.1South Africa Diabetic Neuropathy Treatment Market by Distribution Channel
      • 7.4.4.5.2South Africa Diabetic Neuropathy Treatment Market by Drug Class
      • 7.4.4.5.3South Africa Diabetic Neuropathy Treatment Market by Disorder Type
    • 7.4.4.6Nigeria Diabetic Neuropathy Treatment Market
      • 7.4.4.6.1Nigeria Diabetic Neuropathy Treatment Market by Distribution Channel
      • 7.4.4.6.2Nigeria Diabetic Neuropathy Treatment Market by Drug Class
      • 7.4.4.6.3Nigeria Diabetic Neuropathy Treatment Market by Disorder Type
    • 7.4.4.7Rest of LAMEA Diabetic Neuropathy Treatment Market
      • 7.4.4.7.1Rest of LAMEA Diabetic Neuropathy Treatment Market by Distribution Channel
      • 7.4.4.7.2Rest of LAMEA Diabetic Neuropathy Treatment Market by Drug Class
      • 7.4.4.7.3Rest of LAMEA Diabetic Neuropathy Treatment Market by Disorder Type

Chapter 8.Company Profiles

• 8.1Abbott Laboratories
  • 8.1.1Company Overview
  • 8.1.2Financial Analysis
  • 8.1.3Segmental and Regional Analysis
  • 8.1.4Research & Development Expense
  • 8.1.5Recent strategies and developments:
    • 8.1.5.1Acquisition and Mergers:
    • 8.1.5.2Trial and Approval:
  • 8.1.6SWOT Analysis
• 8.2Eli Lilly And Company
  • 8.2.1Company Overview
  • 8.2.2Financial Analysis
  • 8.2.3Regional Analysis
  • 8.2.4Research & Development Expenses
  • 8.2.5Recent strategies and developments:
    • 8.2.5.1Acquisition and Mergers:
  • 8.2.6SWOT Analysis
• 8.3Pfizer, Inc.
  • 8.3.1Company Overview
  • 8.3.2Financial Analysis
  • 8.3.3Regional & Segmental Analysis
  • 8.3.4Research & Development Expense
  • 8.3.5SWOT Analysis
• 8.4Lupin Limited
  • 8.4.1Company Overview
  • 8.4.2Financial Analysis
  • 8.4.3Regional Analysis
  • 8.4.4Research & Development Expense
  • 8.4.5SWOT Analysis
• 8.5Astellas Pharma, Inc.
  • 8.5.1Company Overview
  • 8.5.2Financial Analysis
  • 8.5.3Regional Analysis
  • 8.5.4Research & Development Expense
  • 8.5.5SWOT Analysis
• 8.6Glenmark Pharmaceuticals Limited
  • 8.6.1Company Overview
  • 8.6.2Financial Analysis
  • 8.6.3Regional Analysis
  • 8.6.4Research & Development Expenses
  • 8.6.5SWOT Analysis
• 8.7Boehringer Ingelheim International GmbH
  • 8.7.1Company Overview
  • 8.7.2Financial Analysis
  • 8.7.3Regional & Segmental Analysis
  • 8.7.4Research & Development Expenses
  • 8.7.5SWOT Analysis
• 8.8Novartis AG
  • 8.8.1Company Overview
  • 8.8.2Financial Analysis
  • 8.8.3Segmental and Regional Analysis
  • 8.8.4Research & Development Expense
  • 8.8.5Recent strategies and developments:
    • 8.8.5.1Acquisition and Mergers:
  • 8.8.6SWOT Analysis
• 8.9McKesson Corporation
  • 8.9.1Company Overview
  • 8.9.2Financial Analysis
  • 8.9.3Segmental Analysis
  • 8.9.4Research & Development Expense
  • 8.9.5SWOT Analysis
• 8.10.GlaxoSmithKline PLC (GSK)
  • 8.10.1Company Overview
  • 8.10.2Financial Analysis
  • 8.10.3Regional Analysis
  • 8.10.4Research & Development Expense
  • 8.10.5SWOT Analysis

Chapter 9.Winning Imperatives of Diabetic Neuropathy Treatment Market

관련자료